

# CITATION REPORT

List of articles citing

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

DOI: 10.1182/blood.v98.10.2887  
Blood, 2001, 98, 2887-93.

**Source:** <https://exaly.com/paper-pdf/32769983/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
219	BCR-ABL as a target for novel therapeutic interventions. <b>2002</b> , 6, 85-101		2
218	Adoptive cellular therapy: a therapeutic reality?. <b>2002</b> , 7, 127-36		
217	[T-cell therapy in oncology. Therapeutic vaccination, allogeneic blood stem cell transplantation and adoptive T-cell transfer]. <b>2002</b> , 127, 755-62		0
216	Cancer vaccines for hematologic malignancies. <b>2002</b> , 9, 138-51		18
215	Cancer vaccination progress. <b>2002</b> , 8, 545-6		2
214	HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. <b>2002</b> , 4, 41-8		17
213	T-cell therapy of leukemia. <b>2002</b> , 9, 114-22		30
212	Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. <b>2002</b> , 262, 5-19		22
211	Oligomeric MHC molecules and their homologues: state of the art. <b>2002</b> , 268, 3-7		10
210	Towards patient-specific tumor antigen selection for vaccination. <b>2002</b> , 188, 164-76		61
209	Cellular therapy for haematological malignancies. <b>2002</b> , 83, 294-304		1
208	New concepts about graft-versus-host and graft-versus-leukaemia-reactions. A summary of the 5th International Symposium held in Munich, 21 and 22 March 2002. <b>2002</b> , 30, 549-56		3
207	Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia. <b>2002</b> , 16, 2341-3		5
206	The basis of T-cell-mediated immunity to chronic myelogenous leukemia. <b>2002</b> , 21, 8668-73		9
205	Chronic myeloid leukemia--advances in biology and new approaches to treatment. <b>2003</b> , 349, 1451-64		755
204	The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. <b>2003</b> , 52, 89-96		29
203	International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK. <b>2003</b> , 52, 403-7		2

202	Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. <b>2003</b> , 52, 761-70	13
201	Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. <b>2003</b> , 151, 646-653	
200	Proteomic tools for quantitation by mass spectrometry. <b>2003</b> , 22, 182-94	138
199	HLA system affects the age-at-onset in chronic myeloid leukemia. <b>2003</b> , 73, 256-62	21
198	The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide. <b>2003</b> , 27, 253-7	3
197	The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. <b>2003</b> , 17, 153-62	63
196	Tumour-associated antigens in multiple myeloma. <b>2003</b> , 120, 3-9	25
195	Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. <b>2003</b> , 120, 63-73	29
194	Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses. <b>2003</b> , 123, 819-29	5
193	Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. <b>2003</b> , 17, 1424-6	47
192	Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. <b>2003</b> , 17, 1243-60	3
191	Myeloproliferative and myelodysplastic syndromes: the future. <b>2003</b> , 17, 1261-9	2
190	Allogeneic stem cell transplantation for chronic myeloid leukemia. <b>2003</b> , 40, 59-71	44
189	Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. <b>2003</b> , 40, 87-96	17
188	Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders. <b>2003</b> , 30, 100-6	7
187	Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. <b>2003</b> , 90, 179-207	30
186	Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. <b>2003</b> , 170, 3046-53	16
185	Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. <b>2003</b> , 2, 388-98	38

184	Leukemia vaccines. <b>2003</b> , 110, 160-70		2
183	Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. <b>2003</b> , 100, 2742-7		361
182	Chronic myeloid leukemia. <b>2003</b> , 2003, 132-52		89
181	Immunotherapy of hematologic malignancy. <b>2003</b> , 2003, 331-49		61
180	New developments in allotransplant immunology. <b>2003</b> , 2003, 350-71		47
179	Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. <i>Blood</i> , <b>2003</b> , 101, 259-64	2.2	117
178	Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. <i>Blood</i> , <b>2003</b> , 102, 2892-900	2.2	185
177	ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. <i>Blood</i> , <b>2003</b> , 102, 4547-54	2.2	58
176	Vaccines in leukemia. <b>2004</b> , 51, 255-70		4
175	Immunotherapy with alloreactive T-cells?. <b>2004</b> , 5 Suppl 3, S91-5		1
174	Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation. <b>2004</b> , 9, 189-98		9
173	Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. <b>2004</b> , 10, 7402-12		52
172	Immunotherapy of hematological malignancies with dendritic cells. <b>2004</b> , 5 Suppl 3, S96-9		4
171	T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. <b>2004</b> , 125, 213-6		6
170	Exploiting alloreactivity for tumour immunotherapy. <b>2004</b> , 87 Suppl 2, 227-9		5
169	DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A(*)2402 resulting in loss of HLA allele expression. <b>2004</b> , 18, 174-6		10
168	Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. <b>2004</b> , 18, 1025-7		5
167	Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). <b>2004</b> , 4, 25		15

166	Chronic myeloid leukemia-still a few questions. <b>2004</b> , 32, 2-10		36
165	Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. <b>2004</b> , 227, 38-50		12
164	Characterization of major histocompatibility complex-associated peptides from a small volume of whole blood. <b>2004</b> , 328, 155-61		2
163	Identification of tumour antigens by serological analysis of cDNA expression cloning. <b>2004</b> , 53, 139-43		53
162	The TBingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. <b>2004</b> , 53, 187-95		104
161	Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. <b>2004</b> , 53, 844-54		150
160	Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. <b>2004</b> , 18, 715-32, xi		4
159	Immunity to chronic myelogenous leukemia. <b>2004</b> , 18, 733-52, xi-xii		9
158	WT1-targeted immunotherapy of leukaemia. <b>2004</b> , 33, 288-90		15
157	Part II: Vaccines for haematological malignant disorders. <b>2004</b> , 5, 727-37		31
156	A gene expressed exclusively in acute B lymphoblastic leukemias. <b>2004</b> , 83, 85-94		1
155	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. <b>2004</b> , 17, 479-492		8
154	Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. <b>2004</b> , 16, 167-73		26
153	Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. <b>2004</b> , 27, 156-60		17
152	A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 103, 1037-42	2.2	159
151	Proteomics techniques and their application to hematology. <i>Blood</i> , <b>2004</b> , 103, 3624-34	2.2	90
150	RELevant gene amplification in B-cell lymphomas?. <i>Blood</i> , <b>2004</b> , 103, 3243-4; author reply 3244-5	2.2	17
149	BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation. <i>Blood</i> , <b>2004</b> , 103, 3245	2.2	9

148	Immunity to tumour antigens. <b>2005</b> , 11, 3501-9	10
147	Immunotherapeutic aspects of stem cell transplantation. <b>2005</b> , 10 Suppl 1, 289-92	3
146	The molecular make-up of a tumour: proteomics in cancer research. <b>2005</b> , 108, 369-83	87
145	Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. <i>Blood</i> , <b>2005</b> , 105, 2016-22	2.2 33
144	Definition of immunogenic antigens in chronic myeloid leukemia (CML) towards the development of cancer vaccines. <b>2005</b> , 29, 1367-9	
143	Combining radiotherapy and immunotherapy: a revived partnership. <b>2005</b> , 63, 655-66	265
142	Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. <b>2005</b> , 19, 289-300	28
141	Antigen-specific cellular immunotherapy of leukemia. <b>2005</b> , 19, 1863-71	50
140	Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF. <b>2005</b> , 115, 951-9	8
139	Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. <b>2005</b> , 54, 297-306	22
138	Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. <b>2005</b> , 54, 219-28	14
137	Retrovirus mediated gene transduction of human T-cell subsets. <b>2005</b> , 54, 759-68	5
136	T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. <b>2005</b> , 54, 1043-58	24
135	Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain. <b>2005</b> , 54, 1106-14	8
134	Peptide Vaccination of Myeloid Leukemia. <b>2005</b> , 131-144	
133	Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. <b>2005</b> , 174, 8210-8	92
132	Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. <b>2005</b> , 46, 663-70	17
131	Vaccine development for chronic myelogenous leukaemia. <b>2005</b> , 365, 631-2	1

130	Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. <b>2005</b> , 5, 1183-92	11
129	Cancer immunity. <b>2005</b> , 129-148	
128	Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens. <b>2006</b> , 21-44	2
127	Emerging drugs in chronic myelogenous leukaemia. <b>2006</b> , 11, 651-64	12
126	Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. <b>2006</b> , 47, 307-12	14
125	Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?. <b>2006</b> , 81, 404-16	8
124	Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15. <b>2006</b> , 19, 281-92	2
123	Donor leukocyte infusions in myeloid malignancies: new strategies. <b>2006</b> , 19, 737-55	30
122	Vaccination for leukemia. <b>2006</b> , 12, 13-8	25
121	Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. <b>2006</b> , 11, 209-20	9
120	Adoptive cellular immunotherapy. 648-660	
119	Stem Cells in Neurodegeneration and Injury. <b>2006</b> , 287-320	
118	A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. <b>2006</b> , 20, 1067-72	15
117	BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. <b>2006</b> , 20, 1738-50	36
116	Generation of tumor-specific T-cell therapies. <b>2006</b> , 20, 61-9	40
115	Immunotherapeutic peptide vaccination with leukemia-associated antigens. <b>2006</b> , 18, 599-604	25
114	The identification of human tumour antigens: Current status and future developments. <b>2006</b> , 55, 996-1003	17
113	Chaperone-rich cell lysates, immune activation and tumor vaccination. <b>2006</b> , 55, 329-38	36

112	Therapeutic opportunities and targets in childhood leukemia. <b>2006</b> , 8, 560-5		3
111	Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. <b>2006</b> , 34, 1709-19		40
110	Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. <b>2006</b> , 315, 153-61		8
109	Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. <b>2006</b> , 47, 1-7		100
108	Tissue Stem Cells. <b>2006</b> ,		3
107	Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia. <b>2006</b> , 5, 211-22		3
106	BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. <b>2006</b> , 66, 5892-900		25
105	Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. <b>2007</b> , 178, 2028-37		31
104	Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. <b>2007</b> , 67, 5300-7		37
103	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. <b>2007</b> , 4, 404-14		31
102	Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. <b>2007</b> , 117, 226-35		5
101	The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. <i>Blood</i> , <b>2007</b> , 110, 2556-60	2.2	16
100	How I treat chronic myeloid leukemia in the imatinib era. <i>Blood</i> , <b>2007</b> , 110, 2828-37	2.2	163
99	Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. <b>2007</b> , 39, 2898-901		7
98	Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—a prostate cancer perspective. <b>2007</b> , 25 Suppl 2, B110-21		23
97	Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. <b>2007</b> , 61, 306-14		11
96	Acute Myelogenous Leukemia. <b>2007</b> ,		
95	Immunotherapy in chronic myelogenous leukemia. <b>2007</b> , 7 Suppl 2, S64-70		4



94	Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. <b>2007</b> , 7 Suppl 2, S81-4	11
93	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. <b>2007</b> , 12, 4568-94	9
92	Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region. <b>2007</b> , 120, 652-657	2
91	Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. <b>2007</b> , 31, 1675-81	2
90	Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. <b>2007</b> , 21, 2287-95	94
89	Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. <b>2007</b> , 137, 297-306	35
88	Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. <b>2007</b> , 148, 189-98	32
87	Optimizing therapy of chronic myeloid leukemia. <b>2007</b> , 35, 144-54	38
86	Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/UL40+ cell transfectants and presented at the cell surface in the context of HLA-E. <b>2007</b> , 322, 128-36	7
85	Immunotherapy of myeloid leukaemia. <b>2007</b> , 56, 943-57	13
84	Immunotherapeutic strategies in chronic myeloid leukemia. <b>2007</b> , 2, 89-94	2
83	Immunomodulation against leukemias and lymphomas: a realistic future treatment?. <b>2008</b> , 65, 101-8	4
82	Immunotherapy for myeloid leukemias: current status and future directions. <b>2008</b> , 22, 1658-64	25
81	A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. <b>2008</b> , 22, 1613-6	37
80	Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. <b>2008</b> , 22, 1090-1	9
79	Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. <b>2008</b> , 41, 483-93	77
78	Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. <b>2008</b> , 80, 461-8	18
77	Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation. <b>2008</b> , 35, 389-93	9

76	Graft-versus-host disease after donor leukocyte infusions: presentation and management. <b>2008</b> , 21, 205-22		54
75	Peptide vaccines for myeloid leukaemias. <b>2008</b> , 21, 391-404		11
74	Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. <b>2008</b> , 21, 437-53		48
73	PR1 vaccination in myeloid malignancies. <b>2008</b> , 7, 867-75		21
72	Immunotherapeutic approaches in chronic myelogenous leukemia. <b>2008</b> , 49, 629-34		9
71	Graft-versus-leukemia effects of transplantation and donor lymphocytes. <i>Blood</i> , <b>2008</b> , 112, 4371-83	2.2	460
70	Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF. <b>2008</b> ,		
69	Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?. <b>2009</b> , 58, 1489-99		12
68	BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors. <b>2009</b> , 58, 1449-57		12
67	Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses. <b>2009</b> , 58, 1459-70		4
66	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. <b>2009</b> , 276, 61-7		7
65	HLA risk markers for chronic myelogenous leukemia in Eastern Canada. <b>2009</b> , 50, 254-9		8
64	The biological basis for immunotherapy in patients with chronic myelogenous leukemia. <b>2009</b> , 16, 141-52		11
63	HPLC and MS analysis for the identification and characterisation of peptides presented in the context of the non-classical human leukocytes antigen (HLA) class I molecule HLA-E. <b>2009</b> , 15, 3325-35		
62	Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. <b>2010</b> , 38, 1209-18		12
61	Immunotherapy of chronic myeloid leukemia: present state and future prospects. <b>2010</b> , 2, 227-41		15
60	Clinical peptide vaccination trials for leukemia patients. <b>2011</b> , 10, 785-99		20
59	Experimental and Applied Immunotherapy. <b>2011</b> ,		

58	Vaccination strategies in lymphomas and leukaemias: recent progress. <b>2011</b> , 71, 1659-74		15
57	Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. <i>Blood</i> , <b>2011</b> , 117, 7174-84	2.2	38
56	BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. <b>2011</b> , 35, 369-72		11
55	Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. <b>2011</b> , 3, 569-76		8
54	Cellular therapy following allogeneic stem-cell transplantation. <b>2011</b> , 2, 409-28		7
53	Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mL-12. <b>2011</b> , 12, 881-7		5
52	Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice. <b>2012</b> , 35, 321-8		4
51	Adoptive cellular immunotherapy. 582-592		
50	Pushing the limits of targeted therapy in chronic myeloid leukaemia. <b>2012</b> , 12, 513-26		225
49	Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. <b>2012</b> , 5, 409-25		15
48	Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. <b>2012</b> , 18, 5761-72		45
47	Defining the pathogenesis of inflammatory and immune diseases through database mining. <b>2012</b> , 4, 2433-41		
46	Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. <b>2013</b> , 62, 715-26		6
45	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- $\gamma$ . <b>2013</b> , 210, 605-21		58
44	Dendritic cell-based immunotherapy for myeloid leukemias. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 496	8.4	28
43	Does the immune system naturally protect against cancer?. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 197	8.4	141
42	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <b>2014</b> , 99, 1441-7		73
41	Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein. <b>2014</b> , 93, 96-102		9

40	Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR/ABL expressing cells. <b>2014</b> , 7, 32-40	2
39	Peptide vaccines for hematological malignancies: a missed promise?. <b>2014</b> , 99, 107-16	6
38	Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients. <b>2014</b> , 166, 619-21	5
37	Adoptive T-cell therapy for Leukemia. <b>2014</b> , 2, 25	13
36	Tumor Antigen and Epitope Identification for Preclinical and Clinical Evaluation. <b>2015</b> , 55-71	
35	A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. <b>2015</b> , 26, 1180-1187	11
34	Bioinformatic prediction and functional characterization of human KIAA0100 gene. <b>2017</b> , 7, 10-18	4
33	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <b>2017</b> , 23, 115-124	7
32	E14a2 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. <b>2017</b> , 102, e297-e299	31
31	Building proteomic tool boxes to monitor MHC class I and class II peptides. <b>2017</b> , 17, 1600061	20
30	Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia. <b>2018</b> , 50, 3789-3796	
29	Myeloid Leukemia Vaccines. <b>2018</b> , 54-71	
28	Is DNA a better assay for residual disease in chronic myeloid leukemia?. <b>2018</b> , 103, 1942-1944	2
27	Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1854	8.4 7
26	Antigen Targets for the Development of Immunotherapies in Leukemia. <b>2019</b> , 20,	6
25	The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2934	8.4 5
24	Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 3004	8.4 13
23	MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity. <b>2019</b> , 191, 48-57	11

22	Neoantigens in Hematologic Malignancies. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 121	8.4	16
21	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
20	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner. <b>2021</b> , 18, 415-426		3
19	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , <b>2021</b> , 2, 487-497	15.4	10
18	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
17	Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation. <i>Cancer Treatment and Research</i> , <b>2009</b> , 144, 497-537	3.5	4
16	Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. <i>Cancer Treatment and Research</i> , <b>2009</b> , 144, 187-208	3.5	2
15	Tumor-Specific Mutations as Targets for Cancer Immunotherapy. <b>2011</b> , 151-172		1
14	CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5127-5141	15.9	20
13	Influence of major transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. <i>Oncotarget</i> , <b>2020</b> , 11, 2560-2570	3.3	4
12	Tumor Vaccines in Leukemia. <b>2007</b> , 329-341		
11	Immune Responses to Stem Cells and Cancer Stem Cells. <b>2009</b> , 505-518		
10	Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	0
9	Tumorimmunologie. <b>2006</b> , 471-484		
8	New Therapies for Chronic Myeloid Leukemia. <b>2007</b> , 165-184		
7	Therapeutic Strategies and Concepts of Cure in CML. <b>2007</b> , 201-218		
6	Identification of neoantigens for individualized therapeutic cancer vaccines.. <i>Nature Reviews Drug Discovery</i> , <b>2022</b> ,	64.1	14
5	The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 883989	8.4	0

- 4 Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.. *Cancer Treatment and Research*, **2022**, 183, 131-159 3.5 ○
- 3 Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
- 2 Neoantigens: promising targets for cancer therapy. **2023**, 8, 3
- 1 Relationship Between Target and Specific Action of Antibody-Drug Conjugates. **2023**, 13-23 ○